The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Yo Mizuno - Tokio Marine Asset Management Co., Ltd., Research Division - Analyst
: [Interpreted] Mizuno, Tokio Marine Asset Management. I have several questions. First about strategy, 3 plus Alpha. Next year or the 2 years later,
it might be 4 plus Alpha. Is it flexible as such?
Question: Yo Mizuno - Tokio Marine Asset Management Co., Ltd., Research Division - Analyst
: [Interpreted] And next is about 8201 data. Brain metastases patients' response rate and PFS are not much different, it said. But 8201, I don't think
that it's delivered to the brain. So regarding metastatic lesion in the brain, how it's acting? So patients are performing okay but having some
neurological symptoms?
Question: Yo Mizuno - Tokio Marine Asset Management Co., Ltd., Research Division - Analyst
: [Interpreted] And 1062, regarding the disclosed data at this time, part 1 and part 2 subjects, the -- basically, the patient background, are they the
same in part 1 and part 2? And maybe some -- either part of a part 1 or 2 have -- or shall I call it, the expansion part? The I-O failure is more in any
one of those parts?
Question: Yo Mizuno - Tokio Marine Asset Management Co., Ltd., Research Division - Analyst
: [Interpreted] And just one point of confirmation. In some slides, in English statement, it said breast cancer doctors don't consider ILD, but lung
cancer physicians, I think they are familiar with ILD. Therefore compared to breast cancer physicians, I think we don't have to too much worry out
those -- the lung-cancer-treating physicians, is that right?
|
